EYEG EyeGate Pharmaceuticals, Inc. Stock Quote

EYEG [NASD]

Index	-	P/E	-	EPS (ttm)	-1.68	Insider Own	1.00%	Shs Outstand	7.06M	Perf Week	1.11%
Market Cap	21.84M	Forward P/E	-	EPS next Y	-0.88	Insider Trans	-96.60%	Shs Float	-	Perf Month	19.74%
Income	-9.50M	PEG	-	EPS next Q	-0.31	Inst Own	31.60%	Short Float	-	Perf Quarter	-60.61%
Sales	0.01M	P/S	1811.10	EPS this Y	20.70%	Inst Trans	0.74%	Short Ratio	0.04	Perf Half Y	-66.73%
Book/sh	1.48	P/B	1.23	EPS next Y	35.10%	ROA	-60.00%	Target Price	-	Perf Year	-50.54%
Cash/sh	0.31	P/C	5.90	EPS next 5Y	-	ROE	-105.00%	52W Range	1.44 - 8.18	Perf YTD	-63.08%
Dividend	-	P/FCF	-	EPS past 5Y	46.50%	ROI	-	52W High	-77.50%	Beta	1.07
Dividend %	-	Quick Ratio	3.10	Sales past 5Y	-	Gross Margin	-	52W Low	27.78%	ATR	0.17
Employees	14	Current Ratio	3.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	47.49	Volatility	11.55% 9.11%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	7.60%	Profit Margin	-	Rel Volume	0.78	Prev Close	1.82
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	2.14M	Price	1.84
Recom	2.00	SMA20	4.97%	SMA50	-17.76%	SMA200	-57.29%	Volume	247,357	Change	1.10%

Dec-22-20

Reiterated

H.C. Wainwright

Buy

$10 → $14

Nov-12-20

Reiterated

H.C. Wainwright

Buy

$12 → $10

Feb-06-18

Reiterated

H.C. Wainwright

Buy

$5 → $3

Apr-07-16

Initiated

Noble Financial

Buy

$10

Feb-01-16

Initiated

Rodman & Renshaw

Buy

$10

Dec-23-15

Initiated

Chardan Capital Markets

Buy

Nov-12-15

Initiated

Maxim Group

Buy

$11

Sep-14-21 12:04PM	36 Stocks Moving In Tuesday's Mid-Day Session Benzinga +7.14%
07:13AM	20 Stocks Moving in Tuesday's Pre-Market Session Benzinga
Sep-09-21 04:15PM	EyeGate to Present at the H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Sep-08-21 06:55AM	EyeGate Pharma Completes Target Enrollment in Phase 2 Proof-of-Concept Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammation GlobeNewswire -9.14%
Aug-12-21 04:15PM	EyeGate Pharma Reports Second Quarter 2021 Financial Results and Provides Business Update GlobeNewswire
Aug-11-21 04:15PM	EyeGate Announces Closing of $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules GlobeNewswire
Aug-10-21 06:55AM	EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules GlobeNewswire -20.48%
Jul-27-21 08:26AM	5 Top Stock Gainers for Tuesday: SiriusXM, Fiserv, EyeGate TheStreet.com +20.83%
05:56AM	EyeGate Skyrockets After It Names a New CEO and Plans for an Acquisition TheStreet.com
Jul-26-21 04:15PM	EyeGate Pharmaceuticals Announces Appointment of Brian M. Strem, Ph.D., as President and Chief Executive Officer GlobeNewswire -5.45%
Jun-30-21 09:56AM	Where Do Hedge Funds Stand On Eyegate Pharmaceuticals, Inc. (EYEG)? Insider Monkey
Jun-14-21 06:55AM	EyeGate Pharma Announces First Patient Dosed for PP-001 in a Phase 2 Proof-of-Concept Ocular Surface Inflammation Study GlobeNewswire +5.57%
May-18-21 05:46AM	EYEG: Maturing and evolving Zacks Small Cap Research +11.44%
May-12-21 04:15PM	EyeGate Pharma Reports First Quarter 2021 Financial Results and Provides Business Update GlobeNewswire
Apr-01-21 06:55AM	EyeGate Pharma Announces the Appointment of Kenneth Gayron and Aron Shapiro to its Board of Directors GlobeNewswire
Mar-25-21 04:15PM	EyeGate Pharma Reports Full Year 2020 Financial Results and Provides Business Update GlobeNewswire
Feb-01-21 06:55AM	EyeGate Pharmaceuticals Announces Management Transition In Support of Strategic Transformation GlobeNewswire
Jan-06-21 06:55AM	EyeGate Enters Into Agreement for $8.0 Million Private Placement GlobeNewswire
Dec-30-20 08:00AM	EYEG: Expanding the pipeline Zacks Small Cap Research
Dec-21-20 10:10AM	Biopharma M&A Continues: Agios Sells Oncology Portfolio, NantKwest's Reverse Merger With ImmunityBio, Eyegate Picks Up Panoptes Benzinga +45.94%
08:12AM	Benzinga Pro's Top 5 Stocks To Watch For Monday, Dec. 21, 2020: EYEG, NKE, ZM, WMT, AIM Benzinga
06:55AM	EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma GlobeNewswire
Nov-30-20 04:38AM	EYEG: Looking Ahead to 2021 Zacks Small Cap Research
Nov-09-20 04:15PM	EyeGate Pharma Reports Third Quarter 2020 Financial Results and Provides Business Update ACCESSWIRE
Sep-28-20 11:05AM	EYEG: Raising Target on positive pipeline progress Zacks Small Cap Research
Sep-25-20 10:48AM	How Much Does EyeGate Pharmaceuticals' (NASDAQ:EYEG) CEO Make? Simply Wall St. +6.30%
Sep-08-20 06:55AM	EyeGate Pharma to Present at H.C. Wainwright 22nd Annual Global Investment Conference ACCESSWIRE +5.00%
Aug-12-20 06:55AM	EyeGate Pharma Confirms Path Forward with FDA To Develop Combination Product ACCESSWIRE +31.22%
Aug-06-20 04:15PM	EyeGate Pharma Reports Second Quarter 2020 Financial Results and Provides Business Update ACCESSWIRE
Jul-14-20 06:55AM	EyeGate Pharma to Proceed with PE Pivotal Study ACCESSWIRE
Jun-11-20 06:55AM	EyeGate Pharma Receives Positive Feedback from FDA Regarding Ocular Bandage Gel Packaging ACCESSWIRE
Jun-01-20 06:55AM	EyeGate Pharma to Present at Jefferies 2020 Virtual Healthcare Conference ACCESSWIRE
May-19-20 09:11AM	EYEG: Solid results moving towards regulatory filings later this year Zacks Small Cap Research
May-06-20 04:15PM	EyeGate Pharma Reports First Quarter 2020 Financial Results and Provides Business Update ACCESSWIRE
09:10AM	EYEG: An Active 2020 with More to Come Zacks Small Cap Research
Apr-01-20 09:04AM	Company News for Apr 1, 2020 Zacks
Mar-31-20 06:55AM	EyeGate Pharma Announces Positive Topline Data in Follow-on Dry Eye Pilot Study ACCESSWIRE +25.30%
Mar-04-20 04:15PM	EyeGate Pharma Reports Full Year 2019 Financial Results and Provides Business Update ACCESSWIRE
Jan-06-20 06:55AM	EyeGate Pharma Completes Enrollment in Follow-on PE Pilot Study ACCESSWIRE
Jan-03-20 10:25AM	EyeGate Announces Completion of $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules ACCESSWIRE
Dec-31-19 09:25AM	EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules ACCESSWIRE -17.87%
Dec-17-19 06:55AM	EyeGate Pharma Receives $1.9 Million from Exercised Warrants ACCESSWIRE
Dec-02-19 06:55AM	EyeGate Pharma Announces Additional Positive Top-Line Data in PRK Pivotal Study ACCESSWIRE
Nov-22-19 09:02AM	Benzinga Pro's Top 5 Stocks To Watch For Fri., Nov. 22, 2019: TSLA, UBER, SPLK, EYEG, WKHS Benzinga +48.02%
08:37AM	EyeGate shares jump on data for eye treatment data MarketWatch
06:55AM	EyeGate Pharma Hits Primary Endpoint in PRK Pivotal Study ACCESSWIRE
Nov-14-19 10:15AM	EYEG: OBG-PRK Pivotal Data Upcoming, 2020 Launch? OBG-PE Pre-Pivotal Study Moving Quick, Pivotal in 2020? Zacks Small Cap Research -13.43%
Nov-07-19 06:55AM	EyeGate Pharma Reports Third Quarter 2019 Financial Results and Provides Business Update ACCESSWIRE
Oct-09-19 06:55AM	EyeGate Pharma Enrolls First Patient in Follow-on PE Pilot Study ACCESSWIRE
06:55AM	EyeGate Pharma Completes Randomization in Pivotal Study ACCESSWIRE
Sep-30-19 06:55AM	EyeGate Enters Into Agreement for $1.9 Million Private Placement ACCESSWIRE
Sep-23-19 06:55AM	EyeGate Pharma Regains Nasdaq Listing Compliance ACCESSWIRE +9.82%
Sep-16-19 06:55AM	EyeGate Pharma Reaches 75% Randomization of Patients in Pivotal Study ACCESSWIRE
Sep-03-19 06:55AM	EyeGate Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference ACCESSWIRE
Aug-29-19 12:45PM	EyeGate Pharma Announces Reverse Stock Split Effective August 30, 2019 ACCESSWIRE
Aug-26-19 06:55AM	EyeGate Pharma Reaches 50% Randomization of Patients in Pivotal Study ACCESSWIRE +6.35%
Aug-08-19 06:55AM	EyeGate Pharma Reports Second Quarter 2019 Financial Results and Provides Business Update ACCESSWIRE -6.82%
Aug-05-19 12:21PM	A Look At Benzinga Pro's Most-Searched Tickers For August 5, 2019 Benzinga
09:00AM	Eyegate Pharmaceuticals Receives FDA Approval To Begin PE Pilot Study Benzinga
06:55AM	EyeGate Pharma Receives Approval from FDA to Initiate PE Pilot Study ACCESSWIRE
Jul-31-19 06:55AM	EyeGate Pharma Announces Randomization of First 25% of Patients in Pivotal Study ACCESSWIRE
Jul-09-19 06:55AM	EyeGate Files FDA Submission to Initiate PE Pilot Study ACCESSWIRE
Jun-26-19 06:55AM	EyeGate Announces First Patient Enrolled in PRK Pivotal Study ACCESSWIRE
Jun-05-19 10:00AM	EYEG: FDA Approves IDE. We Like Chances of Success of Upcoming OBG-PRK Pivotal Study Zacks Small Cap Research +5.24%
Jun-03-19 06:55AM	EyeGate Receives Approval from FDA to Initiate PRK Pivotal Study ACCESSWIRE +23.46%
May-14-19 06:55AM	EyeGate Pharma Receives Positive Nasdaq Listing Determination ACCESSWIRE
May-08-19 04:15PM	EyeGate Pharma Reports First Quarter 2019 Financial Results and Provides Business Update ACCESSWIRE +8.72%
May-02-19 02:00PM	EYEG: EYEG Submits IDE to FDA Seeking Approval to Commence Pivotal PRK Study Zacks Small Cap Research
06:55AM	EyeGate Files IDE with FDA for PRK Pivotal Study ACCESSWIRE
Mar-28-19 10:00AM	EYEG: Our Take On EYEG Moving Towards OBG-PRK Pivotal Study Zacks Small Cap Research
Mar-26-19 06:55AM	EyeGate Confirms Path to De Novo Filing with FDA ACCESSWIRE -13.45%
Mar-01-19 04:05PM	EyeGate Pharmaceuticals Reports Full Year 2018 Financial Results and Provides Business Update ACCESSWIRE
Jan-29-19 06:55AM	EyeGate Pharmaceuticals to Present at BIO CEO & Investor Conference in New York City GlobeNewswire
Jan-16-19 06:55AM	EyeGate Pharmaceuticals Announces Meeting Date with FDA GlobeNewswire -12.35%
Nov-30-18 12:30PM	EYEG: Is EyeGate Eyeing FDA Filings Following Positive OBG Data in Both PRK and PE? Zacks Small Cap Research
Nov-21-18 08:45AM	Investor Expectations to Drive Momentum within Atomera, YogaWorks, Cellect Biotechnology, Eyegate Pharmaceuticals, Zealand Pharma A/S, and Polar Power Discovering Underlying Factors of Influence GlobeNewswire
Nov-14-18 11:20AM	Drug Sales Up, Biotech Stocks Down, Here's a Profit Opportunity ACCESSWIRE
06:50AM	Todays Research Reports on Stocks to Watch: Viking Therapeutics and EyeGate Pharmaceuticals ACCESSWIRE
Nov-13-18 04:05PM	EyeGate Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
09:50AM	4 Healthcare Stocks Investors Are Watching In November ACCESSWIRE
06:55AM	EyeGate Pharma Announces Positive Results in Second PRK Study GlobeNewswire
06:55AM	EyeGate Pharma Announces Positive Results in Punctate Epitheliopathy Study GlobeNewswire
Oct-02-18 06:55AM	EyeGate Pharmaceuticals Signs Technology Transfer and License Agreement with SentrX Animal Care GlobeNewswire
Sep-28-18 11:45AM	EYEG: Focus Is On OBG As U.S. Pilot Studies Fully Enrolled. Data Expected Q4. EGP-437 Ph3 AE Data Disappoints Zacks Small Cap Research
Sep-25-18 06:55AM	EyeGate Pharmaceuticals Granted Additional 180 Days to Comply With Nasdaq Listing Rules GlobeNewswire
Sep-24-18 06:55AM	EyeGate Pharmaceuticals Completes Enrollment in Both PRK and PE Pilot Studies GlobeNewswire
Sep-04-18 08:31AM	EyeGate Announces Randomization of First Patients in Study for Punctate Epitheliopathies GlobeNewswire
08:30AM	EyeGate Announces Top-Line Results for Phase 3 Trial of EGP-437 in Anterior Uveitis GlobeNewswire
Aug-29-18 08:30AM	EyeGate Pharmaceuticals Announces Participation at the H.C. Wainwright 20th Annual Global Investment Conference GlobeNewswire
Aug-20-18 08:30AM	EyeGate Announces Enrollment of First Patient in PRK Pilot Study GlobeNewswire
Aug-07-18 08:30AM	EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf GlobeNewswire
Aug-03-18 08:30AM	EyeGate Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update GlobeNewswire
Jul-26-18 09:30AM	EYEG: IDEs Approved. Both OBG Clinical Studies Set to Kick-Off Zacks Small Cap Research
09:20AM	EYEG: IDEs Approved. Both OBG Clinical Studies Set to Kick-Of Zacks Small Cap Research
Jul-24-18 08:30AM	EyeGate Announces FDA Approval of Two IDE Submissions for Ocular Bandage Gel GlobeNewswire
Jul-10-18 07:45AM	Free Pre-Market Technical Pulse on FibroGen and Three More Biotech Stocks ACCESSWIRE
Jun-22-18 08:30AM	EyeGate Addresses Final FDA Action Item with Submission of IDE Amendment for Ocular Bandage Gel GlobeNewswire
Jun-11-18 07:00AM	Blog Exposure - FibroGen Completed Enrollment in US Phase-3 Clinical Program for Roxadustat in CKD Associated Anemia ACCESSWIRE
May-30-18 08:30AM	EyeGate Files Supplement to Investigational Device Exemption to Commence Study in Punctate Epitheliopathy using the EyeGate Ocular Bandage Gel GlobeNewswire
May-29-18 10:35AM	EYEG: 3 of 4 FDA Questions Answered, OBG-PRK Study On-Track for Q3 Start Zacks Small Cap Research

EyeGate Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveitis and diabetic macular edema; and PaniDrop, which is in Phase I safety study for multiple diseases that affect the ocular surface and anterior region of the eye, comprising of allergic conjunctivitis, viral conjunctivitis, and dry eye disease. The company also develops ocular bandage gel, a modified form of the natural polymer hyaluronic acid for corneal wound repair, and punctate epitheliopathies with a focus on dry eye. The company has license agreements with BioTime, Inc. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ARMISTICE CAPITAL, LLC	10% Owner	Aug 02	Sale	2.40	192,775	463,046	785,000	Aug 03 05:09 PM
ARMISTICE CAPITAL, LLC	10% Owner	Jul 30	Sale	2.69	68,188	183,562	977,775	Aug 03 05:09 PM
ARMISTICE CAPITAL, LLC	Director	Jul 29	Sale	3.00	400,000	1,200,000	1,045,963	Jul 29 07:59 PM
ARMISTICE CAPITAL, LLC	Director	Jul 28	Sale	3.28	375,443	1,232,617	1,445,963	Jul 29 07:59 PM
ARMISTICE CAPITAL, LLC	Director	Jul 27	Sale	5.09	2,377,695	12,113,647	1,821,406	Jul 29 07:59 PM
ARMISTICE CAPITAL, LLC	Director	Jan 06	Buy	5.22	1,531,101	8,000,003	3,346,601	Jan 08 08:31 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience